290 related articles for article (PubMed ID: 33971270)
21. The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders.
Roskoski R
Pharmacol Res; 2018 Mar; 129():65-83. PubMed ID: 29408302
[TBL] [Abstract][Full Text] [Related]
22. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs.
Roskoski R
Pharmacol Res; 2019 Jan; 139():471-488. PubMed ID: 30508677
[TBL] [Abstract][Full Text] [Related]
23. Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers.
Roskoski R
Pharmacol Res; 2017 Mar; 117():343-356. PubMed ID: 28077299
[TBL] [Abstract][Full Text] [Related]
24. ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors.
Roskoski R
Pharmacol Res; 2014 Sep; 87():42-59. PubMed ID: 24928736
[TBL] [Abstract][Full Text] [Related]
25. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
Roskoski R
Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
[TBL] [Abstract][Full Text] [Related]
26. Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas.
Roskoski R
Pharmacol Res; 2017 Jun; 120():116-132. PubMed ID: 28330784
[TBL] [Abstract][Full Text] [Related]
27. The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders.
Roskoski R
Pharmacol Res; 2018 Jul; 133():35-52. PubMed ID: 29704617
[TBL] [Abstract][Full Text] [Related]
28. KLIFS: an overhaul after the first 5 years of supporting kinase research.
Kanev GK; de Graaf C; Westerman BA; de Esch IJP; Kooistra AJ
Nucleic Acids Res; 2021 Jan; 49(D1):D562-D569. PubMed ID: 33084889
[TBL] [Abstract][Full Text] [Related]
29. Aromatic Rings as Molecular Determinants for the Molecular Recognition of Protein Kinase Inhibitors.
Zhu Y; Alqahtani S; Hu X
Molecules; 2021 Mar; 26(6):. PubMed ID: 33810025
[TBL] [Abstract][Full Text] [Related]
30. FMS-like tyrosine kinase 3 (FLT3) inhibitors: Molecular docking and experimental studies.
Mashkani B; Tanipour MH; Saadatmandzadeh M; Ashman LK; Griffith R
Eur J Pharmacol; 2016 Apr; 776():156-66. PubMed ID: 26896780
[TBL] [Abstract][Full Text] [Related]
31. KiSSim: Predicting Off-Targets from Structural Similarities in the Kinome.
Sydow D; Aßmann E; Kooistra AJ; Rippmann F; Volkamer A
J Chem Inf Model; 2022 May; 62(10):2600-2616. PubMed ID: 35536589
[TBL] [Abstract][Full Text] [Related]
32. Targeting ERK1/2 protein-serine/threonine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Apr; 142():151-168. PubMed ID: 30794926
[TBL] [Abstract][Full Text] [Related]
33. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
Roskoski R
Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of human UDP-glucuronosyltransferase (UGT) enzymes by kinase inhibitors: Effects of dabrafenib, ibrutinib, nintedanib, trametinib and BIBF 1202.
Korprasertthaworn P; Chau N; Nair PC; Rowland A; Miners JO
Biochem Pharmacol; 2019 Nov; 169():113616. PubMed ID: 31445021
[TBL] [Abstract][Full Text] [Related]
35. KLIFS: a knowledge-based structural database to navigate kinase-ligand interaction space.
van Linden OP; Kooistra AJ; Leurs R; de Esch IJ; de Graaf C
J Med Chem; 2014 Jan; 57(2):249-77. PubMed ID: 23941661
[TBL] [Abstract][Full Text] [Related]
36. Regulatory spine RS3 residue of protein kinases: a lipophilic bystander or a decisive element in the small-molecule kinase inhibitor binding?
Shevchenko E; Pantsar T
Biochem Soc Trans; 2022 Feb; 50(1):633-648. PubMed ID: 35226061
[TBL] [Abstract][Full Text] [Related]
37. KLIFS: a structural kinase-ligand interaction database.
Kooistra AJ; Kanev GK; van Linden OP; Leurs R; de Esch IJ; de Graaf C
Nucleic Acids Res; 2016 Jan; 44(D1):D365-71. PubMed ID: 26496949
[TBL] [Abstract][Full Text] [Related]
38. Small molecule protein kinase inhibitors approved by regulatory agencies outside of the United States.
Roskoski R
Pharmacol Res; 2023 Aug; 194():106847. PubMed ID: 37454916
[TBL] [Abstract][Full Text] [Related]
39. Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms.
Roskoski R
Pharmacol Res; 2016 Nov; 113(Pt A):395-408. PubMed ID: 27641927
[TBL] [Abstract][Full Text] [Related]
40. ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers.
Roskoski R
Pharmacol Res; 2017 Jul; 121():202-212. PubMed ID: 28465216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
